Hallux Mobilization in Patients With Parkinson's Disease
Hallux Mobilization in Patients With Parkinson's Disease
Parkinson's disease is a degenerative disorder of the central nervous system. The motor
 symptoms of Parkinson's disease result from the death of dopamine-generating cells in the
 substantia nigra, a region of the midbrain; the cause of this cell death is unknown. Early in
 the course of the disease, the most obvious symptoms are movement-related; these include
 shaking, rigidity, slowness of movement and difficulty with walking and gait. A
 multidisciplinary intensive rehabilitation treatment (MIRT) is able to improve different
 parameters in PD that are poorly responsive to dopaminergic therapy. In this study, we aim to
 understand whether the passive mobilization of the metatarsophalangeal joint of the hallux
 determines an increase in the joint range in this district, allowing to improve, at least,
 the gait.
Parkinson's disease is a degenerative disorder of the central nervous system. The motor
 symptoms of Parkinson's disease result from the death of dopamine-generating cells in the
 substantia nigra, a region of the midbrain; the cause of this cell death is unknown. Early in
 the course of the disease, the most obvious symptoms are movement-related; these include
 shaking, rigidity, slowness of movement and difficulty with walking and gait. The main
 families of drugs useful for treating motor symptoms are levodopa dopamine agonists and
 Monoamine oxidases-B inhibitors.A multidisciplinary intensive rehabilitation treatment (MIRT)
 is able to improve different parameters in PD that are poorly responsive to the
 pharmacological therapy. In this study, we aim to understand whether the passive mobilization
 of the metatarsophalangeal joint of the hallux determines an increase in the joint range in
 this district, allowing to improve, at least, the gait in patients with PD. In this course,
 we will evaluate whether passive mobilization of this joint, lead to positive effects on the
 freezing of gait and on the festination.
Inclusion Criteria:

 PD patients stage 3 H&Y with FOG

 Exclusion Criteria:

 we excluded patients with atypical parkinsonism, with other concomitant neurological
 conditions (with cerebrovascular etc.), with joint disorders, muscle disorders or with
 other orthopedic conditions.